Zhi-Hong Liu, M.D.
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
3 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
Role: lead
The Clinical Efficacy of DFPP in Patients With AAGN
Role: lead
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Role: lead
An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
Role: lead
Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis
Role: lead
Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis
Role: lead
Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
Role: lead
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
Role: lead
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
Role: lead
All 9 trials loaded